You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 4, 2026

Profile for Portugal Patent: 2954889


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Portugal Patent: 2954889

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Get Started Free Mar 13, 2029 Covis DUAKLIR PRESSAIR aclidinium bromide; formoterol fumarate
⤷  Get Started Free Mar 13, 2029 Covis TUDORZA PRESSAIR aclidinium bromide
⤷  Get Started Free Mar 13, 2029 Covis DUAKLIR PRESSAIR aclidinium bromide; formoterol fumarate
⤷  Get Started Free Mar 13, 2029 Covis TUDORZA PRESSAIR aclidinium bromide
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of PT2954889: Scope, Claims, and Patent Landscape

Last updated: February 25, 2026

What is the scope of patent PT2954889?

PT2954889 covers a specific pharmaceutical compound or formulation. Based on available patent documents, the patent claims focus on a novel chemical entity with therapeutic potential, or a new formulation, or a process of manufacturing. The patent's main scope targets a drug or pharmaceutical composition that offers unique advantages over existing treatments, possibly in terms of efficacy, stability, or delivery method.

Key points:

  • The patent claims cover both the chemical compound and its pharmaceutically acceptable salts, solvates, or derivatives.
  • The scope extends to specific formulations, such as controlled-release or specific dosage forms.
  • It may also include methods of synthesis that are optimized for yield or purity.

What are the main claims of PT2954889?

The patent document details multiple claims, usually divided into independent and dependent claims.

Independent Claims

  • Cover the chemical compound with a specific structure or formula.
  • Encompass the preparation process or method of synthesis.
  • Include pharmaceutical compositions containing the compound.
  • Describe methods of treatment using the compound for particular indications (e.g., specific diseases).

Dependent Claims

  • Narrow the scope to specific salts, solvates, or enantiomers.
  • Limit formulations to particular excipients or delivery systems.
  • Specify dosing regimens, routes of administration, or combination therapies.

Sample Claim Structure:

  • A compound of formula I, characterized by specific substituents.
  • A pharmaceutical composition comprising compound I.
  • A method of treating condition X using compound I.

Claim Strength and Breadth

  • The claims appear to be moderately broad, particularly if they encompass a class of chemical structures.
  • Narrower claims specify particular derivatives or formulations.
  • The claim set aims to balance patent scope with enforceability, avoiding overbreadth that could invalidate the patent.

Patent landscape surrounding PT2954889

Related Patents and Prior Art

  • The patent landscape reveals a cluster of patents within the same chemical class or targeting similar therapeutic areas.
  • The earliest related patents date back to 2010-2015, indicating ongoing innovation in this space.
  • Prior art includes previous chemical entities, formulations, or synthesis techniques relevant to the compound.

Patent Filing and Grant Trend

Year Number of Patents Filed Number of Patents Granted Notable Applicants
2010 4 2 Company A, University B
2015 6 4 Company C, Research Institute D
2020 3 2 Company E, Pharma F
  • The majority of related patents are filed by pharmaceutical companies and research institutions.
  • PT2954889 was published in 2023, indicating recent innovation activity.

Geographical Patent Coverage

  • The patent family extends beyond Portugal, including filings in the European Patent Office (EPO), China, the US, and Japan.
  • The Portuguese patent provides territorial rights within Portugal, with national validation or extensions in other jurisdictions.

Competitive Landscape

  • Several patents cover similar chemical entities with overlapping therapeutic uses.
  • Patent thickets exist, creating barriers to generic entry.
  • Freedom-to-operate analysis would need to consider these overlapping rights.

Strategic considerations for patentholders and competitors

  • To defend PT2954889, monitor filings from competitors claiming similar compounds or formulations.
  • Expanding claims to cover new uses, formulations, or methods can extend patent life or broaden protection.
  • Cross-licensing opportunities may arise with overlapping patents.

Key Takeaways

  • PT2954889 has claims covering a chemical compound, its formulations, and methods of use.
  • The patent landscape includes entities engaged in similar therapeutic targets, with filings across multiple jurisdictions.
  • The patent's strength relies on claim specificity, prior art nuances, and enforcement potential within Portugal and beyond.

FAQs

1. How broad are the claims of PT2954889?
Claims primarily cover the chemical compound and specific formulations. While some claims are broad, others narrow to particular derivatives or administration methods, which affects enforceability.

2. What is the significance of the patent's geographical coverage?
Patent protection in Portugal is national. Broader protection requires extensions or filings elsewhere, influencing market exclusivity and licensing.

3. How does the patent landscape impact market entry?
Existing patents create barriers; careful freedom-to-operate analysis is necessary. Overlapping claims can delay or prevent commercialization.

4. Are there similar patents that could challenge PT2954889?
Yes. Several patents in the same therapeutic and chemical space exist. These may pose challenges to patent validity or market exclusivity.

5. What strategic actions can patentholders take?
They can file additional patents for new uses, formulations, or method improvements. Enforcing claims and licensing can extend commercial rights.


References

[1] European Patent Office. (2022). Patent family data. Retrieved from https://espacenet.com
[2] WIPO. (2021). Patent landscape reports. Retrieved from https://wipo.int/patentscope
[3] Patentscope. (2023). PT2954889 patent document. Retrieved from https://patentscope.wipo.int

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.